Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Puriblood Medical Co., Ltd., based in Hsinchu City, Taiwan, and established in 2016, specializes in manufacturing and distributing advanced solutions for blood component separation. The company's diverse product portfolio features filters designed for leukoreduction in various blood products, including red blood cells, platelets, and whole blood. They also provide immediate filtration systems for whole blood, alongside Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. A key innovation from Puriblood Medical is its proprietary P-Tex Technology, which leverages a bio-inspired molecular design based on a zwitterionic copolymer structure.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.